Karen is the Director of Business Development, High Impact Clinical Trials Program at the Ontario Institute for Cancer Research in Toronto, Canada. Karen is also the Executive Director for the new Canadian Cancer Clinical Trial Network (3CTN). The focus of Karen’s work at the OICR and 3CTN is to collaborate with stakeholders in clinical research to achieve enhancements and efficiencies in their infrastructure and processes to enhance the conduct of clinical trials.
Karen holds Masters and Bachelors of Science degrees in Nursing. She graduated with Honours and is a member of Sigma Theta Tau, the Honour Society of Nursing. Karen is certified in several areas, including Oncology, Clinical Research, Nursing Management and Administration, Palliative care, Obstetrics and Gynecology. She has thirty-six years of professional experience, in the Netherlands and in Canada, both in the pharmaceutical industry and in the public health system in a variety of positions, with a focus on Oncology and clinical research. In the pharmaceutical industry, Karen was employed in several positions in clinical development, operations, and medical communications areas. In the public health system her positions have ranged from staff nurse to educator, nurse-manager, research coordinator and manager; and director.
Karen is one of the founding members and chair of the board of directors of the Network of Networks (N2), a not for profit organization, which aims to enhance Canada’s clinical research capability and capacity, by providing clinical research professionals with the necessary tools and programs to conduct high quality research with integrity, efficiency and continuous quality improvement; acting as a national voice, advocating on behalf of membership for issues affecting or influencing clinical research in Canada; and serving as a national alliance, bridging regional and provincial initiatives. N2 fosters collaboration among stakeholder groups to strengthen Canada’s research enterprise.